Pre-market Hot Trades in US Stocks
Incannex Healthcare pre-market up 38.32%. Based on recent important news:
<ol>
<li>On July 30, Incannex Healthcare announced it would continue to evaluate all clinical data and plans to complete a full clinical study report in the coming months. This news boosted market confidence, leading to a pre-market increase of 38.32% in stock price.</li>
</ol>
Volcon, pre-market down 9.72%. Based on recent key news:
<ol>
<li>
On July 28, Volcon announced the purchase of 316.8 bitcoins for $37.3 million, bringing its total holdings to 3,500.18 bitcoins, with a total investment of approximately $412 million. The market expressed concerns over its high-risk investment strategy, leading to a decline in stock price.
</li>
<li>
On July 28, Volcon announced it would change its name to Empery Digital Inc., a move interpreted by the market as a strategic transformation of the company, increasing uncertainty and further pressuring the stock price.
</li>
<li>
On July 28, Volcon issued a statement emphasizing that its business faces significant risks and uncertainties, leading investors to doubt the company's prospects and putting pressure on the stock price.
</li>
</ol>
Top Gainers in Pre-market US Stocks
Replimune pre-market up 70.93%. Based on recent key news:
<ol>
<li>
On July 28, Robbins LLP reminded shareholders that a class action lawsuit has been filed against Replimune, involving investors who purchased or acquired Replimune securities between November 22, 2024, and July 21, 2025. This news attracted market attention and drove the stock price up.
</li>
<li>
On July 29, James Wilson, a securities litigation partner at Faruq &amp; Faruq, LLP, urged investors with losses exceeding $50,000 to contact him to discuss available options. This further sparked investor interest, pushing the stock price to continue rising.
</li>
<li>
On July 30, Wolf Haldenstein Adler Freeman &amp; Herz LLP announced it had filed a class action lawsuit on behalf of all individuals or entities that purchased Replimune securities. This news increased market confidence in the company's future, leading to a significant rise in stock price.
</li>
</ol>
BioNexus Gene Lab pre-market up 61.43%. Based on recent important news:
<ol>
<li>
On June 24, BioNexus Gene Lab appointed Chong Set Fui as the new CFO, following the resignation of former CFO Su-Leng Tan Lee. This personnel change may enhance market confidence in the company's management, driving the stock price up.
</li>
<li>
On June 23, Standard BioTools sold its Somalogic division, which, although not directly related to BioNexus, indicates an active merger and acquisition trend in the gene-related industry, potentially boosting market sentiment indirectly
On June 25, Nano Labs announced a $1 billion BNB reserve plan. Although there is no direct connection with BioNexus, it demonstrates the market's interest in the combination of biotechnology and blockchain, which may indirectly affect investors' confidence in related fields.
</li>
</ol>
Tigo Energy rose 34.96% in pre-market trading. Based on recent important news:
<ol>
<li>
On July 29, Tigo Energy reported second-quarter revenue of $24.1 million, exceeding market expectations of $21.5 million, driving the stock price up.
</li>
<li>
On July 29, the company raised its full-year revenue forecast for 2025 to $100 million to $105 million, indicating strong market growth potential.
</li>
<li>
On July 29, analysts rated Tigo Energy as &#34;Buy&#34; and predicted a 12-month price target of $3.25, which is 62.5% higher than the previous day's closing price
</li>
</ol>

IXHL

VLCN

EMPD

Incannex Healthcare pre-market up 38.32%; Volcon pre-market down 9.72%; Replimune pre-market up 70.93%; BioNexus Gene Lab pre-market up 61.43%; Tigo Energy pre-market up 34.96%

Pre-market hot trades in US stocks: Incannex Healthcare up 38.32% in pre-market; Volcon down 9.72% in pre-market